Prograf® granules (tacrolimus)

Policy # 00687
Original Effective Date: 08/14/2019
Current Effective Date: 09/12/2022

 Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider Prograf® granules (tacrolimus) to be eligible for coverage** when the patient selection criteria are met.

Patient Selection Criteria

Coverage eligibility for Prograf granules (tacrolimus) will be considered when the following criteria are met:

- Patient is younger than 18 years of age; AND
- Patient meets one of the following:
  - Patient has a gastrostomy tube (G-tube) or is otherwise unable to swallow tablets and/or capsules AND is NOT taking any other medications in tablet and/or capsule form; OR
  - Patient requires a dosage that can ONLY be met with the granule dosage form.

(Note: The above two patient selection criteria are additional Company requirements for coverage eligibility and will be denied as not medically necessary** if not met).

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of Prograf granules (tacrolimus) when the patient is able to swallow tablets and/or capsules, when the patient is taking other medications in tablet and/or capsule form, or if the patient requires a dosage that can be met with the capsule form to be not medically necessary.**
Prograf® granules (tacrolimus)

Policy #  00687
Original Effective Date:  08/14/2019
Current Effective Date:  09/12/2022

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of Prograf granules (tacrolimus) in patients 18 years of age or older to be investigational.*

Background/Overview
Prograf is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Prograf is supplied as 0.5, 1, and 5 mg capsules, 5 mg/mL injection, and 0.2 and 1 mg unit dose granule packets. In the package insert, the granules are explicitly mentioned for use in pediatric patients only.

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
Prograf is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

The intent of this policy is to limit this oral liquid dosage form to pediatric patients that are unable to swallow and aren’t taking other medications in tablet and/or capsule form OR pediatric patients that need a dose only provided via the granule dosage form.
Prograf® granules (tacrolimus)

Policy # 00687
Original Effective Date: 08/14/2019
Current Effective Date: 09/12/2022

References

Policy History
Original Effective Date: 08/14/2019
Current Effective Date: 09/12/2022
08/01/2019 Medical Policy Committee review
08/14/2019 Medical Policy Implementation Committee approval. New policy.
08/06/2020 Medical Policy Committee review
08/12/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/05/2021 Medical Policy Committee review
08/04/2022 Medical Policy Committee review
08/10/2022 Medical Policy Implementation Committee approval. Updated policy to reflect new indication, which now includes prophylaxis of organ rejection in lung transplants.

Next Scheduled Review Date: 08/2023

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
Prograf® granules (tacrolimus)

Policy #  00687  
Original Effective Date: 08/14/2019  
Current Effective Date: 09/12/2022

2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.